Thymosin a1

This is a demonstration store. You can purchase products like this from Versed.

Lyophilized Thymosin a1 Powder

Overview

Thymosin a1 is a 28‑amino‑acid peptide originally isolated from thymic tissue that acts as a potent immunomodulator across innate and adaptive immunity. Lyophilized Thymosin a1 powder (≥ 98 % purity) preserves peptide integrity and enables precise dosing for in vitro and in vivo research into immunoregulation, antiviral therapy, cancer immunotherapy, and endocrine modulation.

Key Features

• Immune Enhancement: Increases dendritic cell antigen presentation and T‑cell proliferation, improving vaccine response and pathogen clearance PMC.

• Antiviral Activity: Demonstrates efficacy in chronic hepatitis B and C by restoring immune homeostasis and reducing viral load Taylor & Francis Online.

• Oncology Adjunct: Enhances checkpoint‑inhibitor efficacy and mitigates immune‑related toxicities in pre‑clinical cancer models ScienceDirect.

• Anti‑Inflammatory: Suppresses pro‑inflammatory cytokines (e.g., IL‑6, TNF‑α) while promoting regulatory T‑cell profiles, aiding in sepsis and ARDS models PMCScienceDirect.

• Rapid PK Profile: Subcutaneous dosing yields a distribution volume of ~30–40 L and an elimination half‑life < 3 hours, enabling flexible dosing regimens for pulse‑based studies PubMed.

• Safety & Tolerability: Clinical trials report mild adverse events (injection‑site erythema, transient fatigue) with no significant hepatotoxicity, cortisol alteration, or serious immune‑related effects PubMedBMJ

Applications

• In Vitro Immunology: Evaluate T‑cell proliferation, DC maturation, and cytokine secretion in primary cell and cell‑line models PMCPubMed.

• Antiviral Research: Investigate Thymosin a1’s role in inhibiting viral replication and enhancing interferon responses in hepatitis and emerging viral infections PubMedFrontiers.

• Cancer Immunotherapy: Investigate Tα1’s role as an immune checkpoint modulator and its capacity to reduce therapy‑induced adverse events ScienceDirect.

• Autoimmunity & Inflammation: Assess Tα1’s balancing effects on Th1/Th2/Th17 responses in inflammatory disease models PMC.

• Sepsis & Inflammation Models: Test efficacy in LPS‑induced cytokine storm and sepsis models; recent large RCT found no mortality benefit in adult sepsis but supports further mechanistic studies BMJ.

• Endocrine & Aging Studies: Explore Thymosin a1’s potential to modulate age‑related immune decline and thymic involution in aged animal models PMCPMC.

Specifications